Pfizer names former FDA director
Shares of Pfizer Inc. PFE slid 1.20% to $26.42 Wednesday, on what proved to be an all-around mixed trading session for the ...
SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...
The hiring of a former top FDA official amplifies "revolving door" criticism at the worst possible time, STAT's Adam ...
Pfizer has teamed up with Summit Therapeutics to assess whether one of the industry’s hottest cancer candidates works well ...
Bryan Supran, non-executive director and representative of Pfizer, stepped down from the Haleon board of directors. Elizabeth Holmes, the disgraced founder of Theranos, will remain in prison after ...
A study by KFF found that one in four Republican parents now say they've skipped or delayed some childhood vaccines as of ...
Bernstein lowered the firm’s price target on Pfizer (PFE) to $30 from $32 and keeps a Market Perform rating on the shares. The firm notes ...
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why ...
Here's why a gene therapy product originally developed at CHOP spinout Spark Therapeutics was shelved by Pfizer.
Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results